The unconfirmed analyst comments suggest significant positive developments for Cassava Sciences, including the completion of a pivotal Alzheimer's trial and a potential settlement of an SEC investigation. These factors, along with the reiterated buy rating and $107 price target, are likely to drive short-term positive sentiment and price movement.